- Home
- NEGG vs XNCR Comparison
NEGG vs XNCR Comparison
Compare NEGG & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | XNCR |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 881.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NEGG | XNCR |
|---|---|---|
| Price | $25.58 | $12.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 64.4K | ★ 699.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $4.13 | $6.92 |
| 52 Week High | $137.84 | $18.69 |
Technical Indicators
Market Signals| Indicator | NEGG | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 27.73 | 52.47 |
| Support Level | N/A | $12.19 |
| Resistance Level | $47.10 | $13.10 |
| Average True Range (ATR) | 3.23 | 0.82 |
| MACD | -1.18 | 0.00 |
| Stochastic Oscillator | 2.86 | 56.81 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.